IRICoR makes additional investment in ExCellThera

Investment will support clinical trial in sickle cell disease

MONTREAL, Aug. 7, 2020 /CNW Telbec/ – IRICoR, a Centre of Excellence in Commercialization and Research with a focus on drug discovery, announces a new investment in ExCellThera Inc., a clinical-stage cell and molecular medicine company which it co-founded in 2015.

IRICoR’s investment enabled ExCellThera to secure the co-funding required in connection with the grant awarded to it from the California Institute for Regenerative Medicine (CIRM) for a Phase 1 clinical trial using its most advanced technology, ECT-001, for the treatment of severe sickle cell disease.

The study will be conducted in California to demonstrate the safety and feasibility of the Quebec-generated ECT-001 Cell Therapy in children and young adults suffering from severe sickle cell disease.

To read the press release, here

© 2008-2024 IRICoR